Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Department of Clinical Sciences and Community Health, University of Milan, Italy.
Eur Thyroid J. 2023 Mar 10;12(2). doi: 10.1530/ETJ-22-0200. Print 2023 Apr 1.
We have previously observed thyroid dysfunction, i.e. atypical thyroiditis (painless thyrotoxicosis associated with non-thyroidal illness syndrome), in patients with severe acute respiratory syndrome coronavirus 2 disease (Covid-19). This study aimed to analyse the evolution of thyroid dysfunction over time.
One hundred eighty-three consecutive patients hospitalised for severe Covid-19 without known thyroid history were studied at hospital admission (baseline). Survivors were offered 12-month longitudinal follow-up including assessment of thyroid function, autoantibodies and ultrasound scan (US). Patients showing US focal hypoechoic areas suggestive of thyroiditis (focal hypoechogenicity) also underwent thyroid 99mTc or 123I uptake scan.
At baseline, after excluding from TSH analysis, 63 out of 183 (34%) Covid-19 patients commenced on steroids before hospitalisation, and 12 (10%) showed atypical thyroiditis. Follow-up of 75 patients showed normalisation of thyroid function and inflammatory markers and no increased prevalence of detectable thyroid autoantibodies. Baseline US (available in 65 patients) showed focal hypoechogenicity in 28% of patients, of whom 82% had reduced thyroid 99mTc/123I uptake. The presence of focal hypoechogenicity was associated with baseline low TSH (P = 0.034), high free-thyroxine (FT4) (P = 0.018) and high interleukin-6 (IL6) (P = 0.016). Focal hypoechogenicity persisted after 6 and 12 months in 87% and 50% patients, respectively, but reduced in size. After 9 months, thyroid 99mTc/123I uptake partially recovered from baseline (+28%) but was still reduced in 67% patients.
Severe Covid-19 induces mild transient thyroid dysfunction correlating with disease severity. Focal hypoechogenicity, associated with baseline high FT4, IL6 and low TSH, does not seem to be related to thyroid autoimmunity and may persist after 1 year although decreasing in size. Long-term consequences seem unlikely.
我们之前观察到严重急性呼吸综合征冠状病毒 2 型疾病(COVID-19)患者存在甲状腺功能障碍,即异常甲状腺炎(与非甲状腺疾病综合征相关的无痛性甲状腺毒症)。本研究旨在分析甲状腺功能障碍随时间的演变。
对 183 名因严重 COVID-19 住院且无已知甲状腺病史的连续患者在入院时(基线)进行研究。幸存者接受了 12 个月的纵向随访,包括甲状腺功能、自身抗体和超声检查(US)评估。表现出提示甲状腺炎(局灶性低回声)的 US 局灶性低回声区域的患者还接受了甲状腺 99mTc 或 123I 摄取扫描。
在排除 TSH 分析后,183 名 COVID-19 患者中有 63 名(34%)在住院前开始使用类固醇,12 名(10%)表现为异常甲状腺炎。对 75 名患者的随访显示甲状腺功能和炎症标志物正常化,且未发现可检测到的甲状腺自身抗体的患病率增加。基线 US(可在 65 名患者中获得)显示 28%的患者存在局灶性低回声,其中 82%的患者甲状腺 99mTc/123I 摄取减少。局灶性低回声与基线时低 TSH(P=0.034)、高游离甲状腺素(FT4)(P=0.018)和高白细胞介素 6(IL6)(P=0.016)相关。局灶性低回声在分别为 87%和 50%的患者中持续存在 6 个月和 12 个月,但大小减小。9 个月后,甲状腺 99mTc/123I 摄取从基线水平部分恢复(+28%),但仍有 67%的患者减少。
严重 COVID-19 引起轻度短暂性甲状腺功能障碍,与疾病严重程度相关。局灶性低回声与基线时高 FT4、IL6 和低 TSH 相关,似乎与甲状腺自身免疫无关,尽管大小减小,但可能持续 1 年以上。长期后果似乎不太可能。